Halozyme Therapeutics (HALO) Faces Q1 Earnings Test as Revenue Growth Seen Slowing

Halozyme Therapeutics (HALO) is scheduled to report quarterly results after the market close on May 18, 2026, with analysts expecting revenue to rise 34.1% year over year, below the 35.2% growth posted in the year-earlier period. The biopharmaceutical drug delivery company reported $451.8 million in revenue last quarter, up 51.6% from a year earlier and ahead of Wall Street expectations. However, earnings per share missed analyst estimates, and full-year EPS guidance also came in below expectations. Analyst estimates have been largely unchanged over the past 30 days. Sector peers have posted mixed but estimate-beating results: Novavax revenue fell 79.1% year over year but beat expectations by 96.3%, while Moderna revenue rose 260% and topped estimates by 55.8%. Halozyme shares are down 5.3% over the past month, compared with a 6.1% average gain for therapeutics peers. The stock recently traded at $64.22, below the average analyst price target of $85.78.